Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05453799 · ClinicalTrials.gov registry record · Phase 2
Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
A Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Thyroid Gland Anaplastic Carcinoma, sponsored by Northwestern University.
- Active
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 2
- Study locations
NCT05453799 is a Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Thyroid Gland Anaplastic Carcinoma that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 54 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT05453799, a Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Thyroid Gland Anaplastic Carcinoma, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial tests whether vudalimab works to shrink tumors in patients with anaplastic thyroid cancer or hurthle cell thyroid cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as vudalimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- DRUG Vudalimab
Study Locations (2)
Illinois
- Northwestern University - Chicago
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05453799
The ClinicalTrials.gov registry entry for NCT05453799 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Thyroid Gland Oncocytic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Vudalimab is the first listed.
NCT05453799 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT05453799 about?
NCT05453799 is a clinical study titled "Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer". This phase II trial tests whether vudalimab works to shrink tumors in patients with anaplastic thyroid cancer or hurthle cell thyroid cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibo...
What is the current status of trial NCT05453799?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2022-07-21. Estimated completion is 2027-07-15.
What conditions does trial NCT05453799 study?
This clinical trial studies the following conditions: Metastatic Thyroid Gland Oncocytic Carcinoma, Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma.
What interventions are being tested in trial NCT05453799?
The interventions under investigation include: Vudalimab (DRUG).
Who is sponsoring clinical trial NCT05453799?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05453799 being conducted?
This trial has 2 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Thyroid Gland Oncocytic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Metastatic Thyroid Gland Oncocytic Carcinoma
All registered trials for this condition
Locally Advanced Thyroid Gland Anaplastic Carcinoma
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.